

**Epidemiological, clinical profile, and outcomes of patients with prolactinomas taking a high dose cabergoline ($\geq 3\text{mg/week}$):
RESISTANT PROLACTINOMA STUDY**



Prolactinoma study

**A call for all ENEA members around the world
to participate**

ЕНЕА RESISTANT PROLACTINOMA STUDY

Contact

https://eneassoc.org/?page_id=1437


PROTOCOL: Purpose of study:

Epidemiological, clinical profile, and outcomes of patients with prolactinomas **taking a high dose cabergoline ($\geq 3\text{mg/week}$).**


Methods:

- ✓retrospective observational study
- ✓males/ females ≥ 18 years old with prolactinomas and cabergoline treatment at doses $\geq 3\text{ mg/week}$
- ✓SYNERGY2GO platform

treated for at least 6 months with at least 3 mg/week cabergoline without achieving prolactin level normalization




PROTOCOL



Secondary end-points:

1. Definition 'resistant prolactinomas'
2. Assessment of current management
3. Database on resistant prolactinomas

Announcement on December of 2021



Centers Contacted for clarifications

Italy	3
Spain	1
France	1
Turkey	1
Brasil	1
Argentina	1
Serbia	2
Croatia	1
Portugal	1

Type of queries

Number of involved investigators	= 2
Use of platform	= 2
ENEA membershipness	= 1
Protocol clarifications	= 2
Acceptance with no queries	= 2
Demand for extension of the study	= 3

FINDINGS

Centers currently Registered

National and Kapodistrian University of Athens - **GREECE – 2 cases**

Vall d'Hebron- Barcelona – **SPAIN – 4 cases**

University Clinical Centre of Serbia- Belgrade – **SERBIA – 9 cases**

University Hospital Centre Zagreb- Zagreb – **CROATIA - 8 cases**

= 23 cases

FINDINGS: Preliminary results in 23 patients- baseline characteristics

	N (%)
Gender (females/ males)	9 (39) /14 (61)
Race (white/black)	22 (96) / 1 (4)
Age (years)	33 (15-64)
Microadenomas and / Macroadenomas / NR	2 (9) /19 (82) / 2 (9)
Tumour extension (mm) in 19 neoplasms	
Intrasellar extension	24.5 (7-53)
Suprasellar extension	16 (5-77)
Infrasellar extension	22 (8-58)
Parasellar extension	
Hormonal Complications in 19 neoplasms	
Hypopituitarism	13 (68)
Hypothyroidism	6 (32)
Central hypogonadism	17 (89.5)
Central adrenal insufficiency	3 (16)
Growth hormone deficiency	0
Visual field deficiency	6 (32)